Reciprocal co-expression of Fas and Fas ligand in human cholangiocarcinoma

International Journal of Oncology

Volumn 31, Issue 4, 2007, Pages 843-850

  Pan, George ^a   Ahn, Eun Young ^a   Chen, Yabing ^a   Feng, Gong ^a   Reddy, Vishnu ^a   Jhala, Nirag C ^a   McDonald, Jay M ^a,b  

^a University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Cholangiocarcinoma; Fas ligand; Fas APO 1(CD95); NF B

Indexed keywords

FAS ANTIGEN; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; MESSENGER RNA;

APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT TUMOR; CELL CULTURE; ENZYME IMMUNOASSAY; GEL MOBILITY SHIFT ASSAY; GENETICS; HUMAN; IMMUNOLOGY; INTRAHEPATIC BILE DUCT; METABOLISM; NORTHERN BLOTTING; PATHOLOGY; WESTERN BLOTTING;

ANTIGENS, CD95; APOPTOSIS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BLOTTING, NORTHERN; BLOTTING, WESTERN; CHOLANGIOCARCINOMA; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FAS LIGAND PROTEIN; HUMANS; IMMUNOENZYME TECHNIQUES; LUCIFERASES; NF-KAPPA B; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 35848935854     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.4.843     Document Type: Article

References (47)

1. Pickens A, Pan G, McDonald JM, and Vickers SM: Fas expression prevents cholangiocarcinoma tumor growth. J Gastrointest Surg 3: 374-382, 1999.
2. Pan G, Vickers SM, Pickens A, et al: Apoptosis and tumorigenesis in human cholangiocarcinoma cells. Involvement of Fas/APO-1 (CD95) and calmodulin. Am J Pathol 155: 193-203, 1999. (Pubitemid 29318717)
3. Ahn EY, Pan G, Oh JH, et al: The combination of calmodulin antagonists and interferon-gamma induces apoptosis through caspase-dependent and -independent pathways in cholangio-carcinoma cells. Am J Pathol 163: 2053-2063, 2003. (Pubitemid 37310035)
4. Vickers SM, Jhala NC, Ahn EY, et al: Tamoxifen (TMX)/Fas induced growth inhibition of human cholangiocarcinoma (HCC) by gamma interferon (IFN-gamma). Ann Surg 235: 872-878, 2002.
5. Ahn EY, Pan G, Vickers SM and McDonald JM: IFN-gamma upregulates apoptosis-related molecules and enhances Fas-mediated apoptosis in human cholangiocarcinoma. Int J Cancer 100: 445-451, 2002.
6. Owen-Schaub LB, van Golen KL, Hill L and Price JE: Fas and Fas ligand interactions suppress melanoma lung metastasis. J Exp Med 188: 1717-1723, 1998. (Pubitemid 28516116)
7. Worth LL, Lafleur EA, Jia SF and Kleinerman ES: Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep 9: 823-827, 2002.
8. Liu K and Abrams SI: Alterations in Fas expression are characteristic of, but not solely responsible for, enhanced metastatic competence. J Immunol 170: 5973-5980, 2003. (Pubitemid 36682577)
9. Rivoltini L, Carrabba M, Huber V, et al: Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 188: 97-113, 2002. (Pubitemid 35398868)
10. Costello RT, Gastaut JA and Olive D: Mechanisms of tumor escape from immunologic response. Rev Med Interne 20: 579-588, 1999.
11. Saas P, Walker PR, Hahne M, et al: Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 99: 1173-1178, 1997.
12. Houston A, Waldron-Lynch FD, Bennett MW, et al: Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo. Int J Cancer 107: 209-214, 2003. (Pubitemid 37152899)
13. Eberle J, Fecker LF, Hossini AM, et al: CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants. Oncogene 22: 9131-9141, 2003. (Pubitemid 38067988)
14. Igney FH, Behrens CK and Krammer PH: The influence of CD95L expression on tumor rejection in mice. Eur J Immunol 33: 2811-2821, 2003.
15. Mhashilkar AM, Schrock RD, Hindi M, et al: Melanoma differentiation associated gene-7 (mda-7): a novel anti-tumor gene for cancer gene therapy. Mol Med 7: 271-282, 2001.
16. Tada Y, J OW, Takiguchi Y, et al: Cutting edge: a novel role for Fas ligand in facilitating antigen acquisition by dendritic cells. J Immunol 169: 2241-2245, 2002.
17. Hahne M, Rimoldi D, Schroter M, et al: Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274: 1363-1366, 1996.
18. Green DR, Droin N and Pinkoski M: Activation-induced cell death in T cells. Immunol Rev 193: 70-81, 2003.
19. Restifo NP: Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med 6: 493-495, 2000.
20. Kang SM, Schneider DB, Lin Z, et al: Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 3: 738-743, 1997.
21. Saposnik G, Maurino J and Bueri J: Movements in brain death. Eur J Neurol 8: 209-213, 2001.
22. Shimonishi T, Isse K, Shibata F, et al: Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance. Hepatology 32: 761-769, 2000.
23. Ito Y, Takeda T, Sasaki Y, et al: Expression of Fas and Fas ligand reflects the biological characteristics but not the status of apoptosis of intrahepatic cholangiocellular carcinoma. Int J Mol Med 6: 581-586, 2000.
24. Zayzafoon M, Abdulkadir SA and McDonald JM: Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines. J Biol Chem 279: 3662-3670, 2004.
25. Hohlbaum AM, Moe S and Marshak-Rothstein A: Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med 191: 1209-1220, 2000.
26. Abrahams VM, Straszewski SL, Kamsteeg M, et al: Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res 63: 5573-5581, 2003.
27. Schreiber E, Matthias P, Muller MM and Schaffner W: Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 17: 6419, 1989.
28. Tsai JC, Jain M, Hsieh CM, et al: Induction of apoptosis by pyrrolidinedithiocarbamate and N-acetylcysteine in vascular smooth muscle cells. J Biol Chem 271: 3667-3670, 1996. (Pubitemid 26065683)
29. Pan Z, Kravchenko VV and Ye RD: Platelet-activating factor stimulates transcription of the heparin-binding epidermal growth factor-like growth factor in monocytes. Correlation with an increased kappa B binding activity. J Biol Chem 270: 7787-7790, 1995.
30. Rajashekhar G, Loganath A, Roy AC and Mongelli JM: Co-expression of Fas (APO-1, CD95)/Fas ligand by BeWo and NJG choriocarcinoma cell lines. Gynecol Oncol 91: 101-111, 2003.
31. Gastman BR, Atarshi Y, Reichert TE, et al: Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 59: 5356-5364, 1999.
32. Shibakita M, Tachibana M, Dhar DK, et al: Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer. Clin Cancer Res 5: 2464-2469, 1999. (Pubitemid 29437329)
33. Strand S, Hofmann WJ, Hug H, et al: Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat Med 2: 1361-1366, 1996.
34. Nozoe T, Yasuda M, Honda M, et al: Fas ligand expression is correlated with metastasis in colorectal carcinoma. Oncology 65: 83-88, 2003.
35. Chen YL, Wang JY, Chen SH and Yang BC: Granulocytes mediates the Fas-L-associated apoptosis during lung metastasis of melanoma that determines the metastatic behaviour. Br J Cancer 87: 359-365, 2002.
36. Restifo NP: Countering the 'counterattack' hypothesis. Nat Med 7: 259, 2001.
37. O'Connell J, Bennett MW, O'Sullivan GC, et al: Fas counter-attack - the best form of tumor defense? Nat Med 5: 267-268, 1999.
38. Nagata S and Golstein P: The Fas death factor. Science 267: 1449-1456, 1995.
39. Alderson MR, Tough TW, Davis-Smith T, et al: Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 181: 71-77, 1995.
40. Sibley K, Rollinson S, Allan JM, et al: Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 63: 4327-4330, 2003.
41. Su X, Cheng J, Liu W, et al: Autocrine and paracrine apoptosis are mediated by differential regulation of Fas ligand activity in two distinct Jurkat T cell populations. J Immunol 160: 5288-5293, 1998.
42. Watabe M, Hishikawa K, Takayanagi A, et al: Caffeic acid phenethyl ester induces apoptosis by inhibition of NFkappaB and activation of Fas in human breast cancer MCF-7 cells. J Biol Chem 279: 6017-6026, 2004.
43. Lu B, Wang L, Medan D, et al: Regulation of Fas (CD95)-induced apoptosis by nuclear factor-kappaB and tumor necrosis factor-alpha in macrophages. Am J Physiol Cell Physiol 283: C831-C838, 2002.
44. Zheng Y, Ouaaz F, Bruzzo P, et al: NF-kappa B RelA (p65) is essential for TNF-alpha-induced fas expression but dispensable for both TCR-induced expression and activation-induced cell death. J Immunol 166: 4949-4957, 2001.
45. Darville MI and Eizirik DL: Cytokine induction of Fas gene expression in insulin-producing cells requires the transcription factors NF-kappaB and C/EBP. Diabetes 50: 1741-1748, 2001.
46. Kasibhatla S, Brunner T, Genestier L, et al: DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell 1: 543-551, 1998.
47. Matsui K, Fine A, Zhu B, et al: Identification of two NF-kappa B sites in mouse CD95 ligand (Fas ligand) promoter: functional analysis in T cell hybridoma. J Immunol 161: 3469-3473, 1998.